Clinical Trial Update: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the MEK inhibitor MSC1936369B in combination with FOLFIRI in second-line KRAS-mutated metastatic colorectal cancer; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• MSC1936369B (MSC1936369B)

Snippet

Sponsor: EMD Serono | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-10-19